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Background/Purpose: Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in young
children. The population-based burden of RSV hospitalization and the effect of potential risk factors on
the severity of illness were evaluated in Taiwanese children.
Methods: We analyzed the annual population-based incidence, underlying diseases and characteristics of
hospitalizations due to RSV in Taiwanese children under 5 years of age from 2004 to 2007 by using
Taiwan’s National Health Insurance database.
Results: A total of 11,081 children with RSV-associated hospitalization were studied. Average annual 
population-based hospitalization incidence was 1,077 and 232 per 100,000 children-year in children
under 6 months and under 5 years of age, respectively. The peak incidence occurred between 1 and 2 months
of age. The male-to-female incidence risk ratio was 1.4:1 (p < 0.001). There was a significant seasonal dis-
tribution with consistent peaks in the spring and autumn every year (p < 0.001). A total of 373 patients
(3.3%) had repeated RSV infection. The 943 children (8.5%) with underlying diseases were older
(p = 0.001), required longer intensive care unit (ICU) stays (p < 0.001), had a higher rate of endotracheal
intubation (p < 0.05), and incurred higher medical costs (p < 0.001). A total of 888 patients (8%) required
ICU care. Younger age (p < 0.001), prematurity (p < 0.001), cerebral palsy (p < 0.001) and congenital heart
disease (p < 0.001) were independent predictors of requiring ICU care.
Conclusion: RSV infection occurs biennially with peaks in spring and fall in Taiwan. Patients with under-
lying diseases need longer hospital and ICU stays and incur higher medical costs. Younger age, prematu-
rity, congenital heart disease and cerebral palsy are predictors of ICU care.
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Lower respiratory tract infection due to respira-
tory syncytial virus (RSV) is a major cause of mor-
bidity in infants and young children.1 Almost all
children are infected by RSV at least once by 
2 years of age, and approximately 1–2% of in-
fants require hospitalization for RSV-associated
lower respiratory tract infection.2,3 The peak inci-
dence of RSV infection and hospitalization is be-
tween the second and the sixth month of age.4,5
In high-risk groups, such as preterm infants,
younger chronological age, young children with
chronic lung disease, immunodeficient patients
and infants with congenital heart disease, RSV
infections can cause considerable morbidity and
death.6–9 Hospitalization rate and mortality rate in
these higher risk groups are approximately 10%
and 3%, respectively.10 RSV epidemics depend on
geographic location, and cluster during the au-
tumn and last until spring in temperate climates
and generally coincide with the rainy season in
tropical areas.11–14 Treatment of RSV respiratory ill-
ness is mainly supportive, with ribavirin remaining
the specific treatment.15 Monthly palivizumab is
currently recommended in high-risk children as
prophylaxis for RSV infection during winter,16
however, this medication is still very expensive
and in limited supply in Taiwan.17
Nationwide epidemiologic data concerning
RSV is limited and the total burden of RSV infec-
tion remains undefined in Taiwan.18–20 Therefore,
the aims of this population-based study were to
determine severity, risk factors, seasonality, and
medical cost of RSV-associated hospitalization in
Taiwan.
Materials and Methods
Taiwan’s National Health Insurance (NHI) system
implemented in March 1995, covers over 96% of
the Taiwanese population. Through the NHI data-
base, we collected hospital healthcare records from
2004 to 2007 for hospitalized children below the
age of 5 diagnosed with RSV-associated Interna-
tional Classification of Diseases, Ninth Revision,
and Clinical Modification (ICD-9 CM) codes.
These codes included RSV bronchiolitis (ICD-9
CM Code 466.11), viral pneumonia due to RSV
(ICD-9 CM 480.1) and RSV infection (ICD-9 CM
079.6). The underlying diseases were also collected
based on the ICD-9 CM: prematurity (ICD-9 CM
Code 765.10–765.19); congenital heart disease
(ICD-9 CM Code 745.0–747.4); chronic lung
disease (ICD-9 CM code 770.7); cerebral palsy
(ICD-9 CM code 343.9) and hematologic diseases
(ICD-9 CM code 200.2–205.9). We also collected
data on whether the above patients were treated
with intubation of the respiratory tract (ICD-9
procedure code 96.5) or continuous mechanical
ventilation (96.7). Chronic lung disease in pre-
mature infants was defined as a persistent need
for supplemental oxygen at a gestational age of
36 weeks and characteristic findings in the chest
radiography. Hospitalizations were stratified by
patient age: younger than 1 month, 1 to 2 months,
3 to 6 months, 7 to 12 months, 13 to 24 months,
or 25 to 60 months.
We analyzed the RSV-associated hospitaliza-
tion by year, age group, gender, and season. To cal-
culate the annual population-based incidence of
RSV-associated hospitalization, the annual epi-
sodes were divided by the same age-specific, mid-
year gender-specific population of children as
reported between 2004 and 2007 from the Taiwan
census data. We also analyzed the rate of receiv-
ing intensive care unit (ICU) care and compared
length of stay with and without specified under-
lying diseases.
Statistical analysis
Continuous variables were expressed as mean ±
standard deviation (SD) and were compared using
Student t test. Categorical variables were expressed
as absolute and relative frequencies and were com-
pared using the χ2 or Fisher’s exact test. We then
performed simple and multiple logistic regres-
sion analyses to identify independent predictors
of the need of ICU care. Variables were selected
for entry into the regression model if the vari-
ables were significantly associated with the need
for ICU care (p < 0.1) in the univariate analysis. 
A p value of < 0.05 was considered significant.
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Results
Annual incidence
11,081 hospitalizations identified using the RSV
specific ICD codes in children up to 5 years of
age were reported during the 4-year study period:
2,788 in 2004; 2,795 in 2005; 2,607 in 2006; and
2,891 in 2007. No statistically significant difference
was observed in different years. A total of 370 pa-
tients (3.3%) had repeated RSV infection. 276
episodes per 100,000 children-year for boys and
194 episodes per 100,000 children-years for girls
were identified. The male-to-female incidence risk
ratio was 1.4:1 (p< 0.001). The average annual
population-based incidence of RSV-associated
hospitalization was 232 episodes per 100,000 for
all children under the age of 5 years (Table 1). The
average annual incidence peaked in children be-
tween 1 and 2 months of age with 1637 episodes
per 100,000 children-year, which was 7-fold greater
than the overall incidence under 5 years of age.
The average annual incidence of children less
than 1 year of age was 930 episodes per 100,000
children-years. About 70% of RSV-related hospital-
izations occurred in infants. The annual incidence
of RSV-associated hospitalization was highest in
children under 6 months of age in different years
(Figure 1).
Seasonality
RSV-associated hospitalization occurred year-
round in Taiwan. An analysis of seasonal distri-
bution of hospitalization due to RSV (Figure 2)
showed a significant seasonal distribution with a
consistent biennial pattern, with yearly peaks in
the spring and autumn (p < 0.001).
Underlying diseases
Among all the 11,081 RSV-associated inpatients,
one or more underlying diseases were present in
943 (8.5%) children. Among these children, 602
(64%) were premature, 468 (50%) had congenital
heart disease, 59 (6.3%) had chronic lung disease,
30 (3.2%) had cerebral palsy, 14 (1.5%) had Down
syndrome and 10 (1.1%) had hematologic dis-
eases. The children with underlying diseases were
older (p= 0.001), required longer ICU stays
(p< 0.001), needed a higher rate of endotracheal
intubations (p< 0.05), were administered ribavirin
(p< 0.05) and incurred higher medical costs
(p < 0.001). Comparisons between patients with
Table 1. The annual population-based rate of RSV-associated hospitalization in children under 5 years of agea
Year 2004 2005 2006 2007 Average
Sex
Boy 255 269 274 307 276
Girl 180 190 185 223 194
Age (mo)
0–1 437 400 437 446 430
1–2 1608 1491 1569 1879 1637
3–6 1068 1121 1063 1146 1099
7–12 716 781 797 839 783
13–24 250 279 272 328 282
25–60 33 33 25 33 31
aIncidence = episodes per 100,000 children.
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Figure 1. Annual incidence of RSV-associated hospitalization
in children under 5 years of age from 2004 to 2007 in Taiwan.
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and without underlying diseases of RSV-associated
hospitalization are listed in Table 2. The seasonal
occurrence of RSV-associated hospitalization in
the premature and in patients with congenital
heart diseases also peaks in the spring and autumn
(Figure 3).
Risk factors associated with the need for ICU
care, ribavirin and endotracheal intubation
Ninety-two percent of patients were managed ex-
clusively on a general pediatric ward. Compared
with patients managed exclusively in a general pe-
diatric ward, patients requiring ICU care were more
likely to be younger (p< 0.001), to have higher
rates of underlying diseases (p< 0.05) and higher
mortality rates (p< 0.05). One or more risk factors
were present in 7.3% of patients managed exclu-
sively in a general pediatric ward compared with
22.5% of patients requiring ICU care (p< 0.05).
Ribavirin was prescribed in 0.1% of patients
managed exclusively on a general pediatric ward,
while 32.1% of patients admitted to the ICU
(p < 0.05) were treated with this medication.
Patients needing ICU care had longer hospital
stays (12.0 ± 9.6 vs. 5.9 ± 4.1, p< 0.001) and higher
mortality rates (0.9% vs. 0.05%, p < 0.05). The
risk factors associated with the need of ICU care
are listed in Table 3. Multivariate analyses showed
that age [odds ratio (OR), 0.94; 95% confidence
interval (CI), 0.93–0.95, p < 0.001], prematurity
(OR, 1.78; 95% CI, 1.38–2.29, p< 0.001), cerebral
palsy (OR, 15.06; 95% CI, 6.48–33.60, p < 0.001)
and congenital heart disease (OR, 4.50; 95% CI,
3.06–5.78, p < 0.001) were independent predic-
tors of the need for ICU care.
Medical cost
The annual mean cost of hospitalization for 
RSV-associated hospitalization ranged between
84.2 and 93.4 million New Taiwan dollars (NT$)
per year. One hospitalization cost an average of
NT$32,300. The cost per hospitalization was much
higher in patients having underlying disease
(72,672 vs. 28,562, p < 0.001).
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Figure 2. Monthly distribution of RSV-associated hospitalization in children under 5 years of age from 2004 to 2007.
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Table 2. Demographic data and management of RSV-associated hospitalization patients with and without
underlying diseasesa
Underlying diseases
Yes (n = 943) No (n = 10,138)
p
Age (mo) 12.6 ± 10.7 10.4 ± 10.2 0.001
Gender (male) 521 (55.2) 6225 (61.4) < 0.001
O2 use 581 (61.6) 5419 (53.5) < 0.05
ICU care 200 (21.2) 688 (6.8) < 0.05
Ribavirin use 68 (7.2) 223 (2.2) < 0.05
Endotracheal intubation 57 (6.0) 79 (0.8) < 0.05
CPAP 46 (4.9) 111 (1.1) < 0.05
Transfusion 7 (0.8) 17 (0.16) NS
Mortality rate 11 (1.2) 2 (0.02) < 0.01
ICU stay (d) 9.27 ± 8.86 5.70 ± 6.07 < 0.001
Hospital stay (d) 9.9 ± 10.6 6.1 ± 4.00 < 0.001
Medical cost (NT$) 72,672 ± 133,213 28,562 ± 42,551 < 0.001
Medical cost (US$) 2076 ± 3806 816 ± 1216 < 0.001
aData are presented as mean ± SD or n (%). ICU = intensive care unit; CPAP = continuous positive airway pressure; NT$ = New Taiwan
dollar; US$ = United States dollar; NS = not significant.
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Figure 3. Monthly distribution of RSV-associated hospitalization in children with underlying diseases under 5 years of
age from 2004 to 2007. CHD = congenital heart disease; CLD = chronic lung disease; CP = cerebral palsy.
Respiratory syncytial virus in Taiwan
J Formos Med Assoc | 2011 • Vol 110 • No 6 393
Discussion
Our findings from the National Health Insurance
(NHI) system provide a comprehensive view of the
RSV burden among Taiwanese children. Almost
70% of the patients with RSV-associated hospi-
talization are under 12 months of age. Children
with underlying diseases suffered from significant
morbidity and mortality. The seasonal distribution
had a biennial pattern with peaks in the spring
and autumn every year.
The average annual hospitalization rates under
5 years of age were 3 per 1000 children in the
United States and 293 per 100,000 children in
rural Kenya.21,22 The average annual hospitaliza-
tion incidence in Taiwan is lower than the previ-
ous report from the USA and in rural Kenya.21,22
According to the previous studies showing that the
hospitalization rate of RSV infection was around
1–2%,2,3 the total disease burden of RSV infection
would be estimated at about 46,500 to 93,000
per 100,000 children per year in the first year of life
in Taiwan. This is compatible with previous sero-
logic studies that indicate half of the children are
infected during the first year and nearly all children
have antibodies against RSV by the end of the sec-
ond year of life.1,2 The incidence of RSV-related
hospitalizations is highest among young infants
2–6 months of age,5,23 whereas the incidence
peaked among 1–2 months of age in our study.
Furthermore, we found the same result that the
younger the age, the higher the incidence of RSV-
associated hospitalization. In addition to the small
size of the conducting airways and incomplete
development of the lung structure, the less efficient
immune response may explain why an age of less
than 6 months at the time of hospitalization is
associated with a higher likelihood of being hos-
pitalized due to RSV infection.9
Most children with RSV infection who were
hospitalized had no coexisting medical conditions
or characteristics that significantly identified them
as being at greater risk for severe RSV disease, 
except for being under 2 years of age.21 Like other
previous studies,21,24 the vast majority of children
hospitalized for this condition in our study areT
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previously normal babies. Although RSV may cause
severe infections in healthy young children, the
infections are more severe in premature children,
in those with immune deficiency, and in those
with a subjacent illness, such as chronic lung dis-
ease or congenital heart disease.24–26 In previous
analyses, RSV infection is the single most common
principal diagnosis leading to rehospitalization
of premature infants.27 Our findings suggested that
the patients who had underlying diseases needed
longer hospital stay, ICU stay, and incurred higher
medical costs.
The risks of severe complications of RSV-
associated hospitalization are increased in prema-
turely born infants with chronic lung disease and
in children with unstable hemodynamic congeni-
tal heart disease, as well as with severe neuromus-
cular impairment.28–31 Of all risk factors assessed,
the following were found to be independent risk
factors for the development of severe RSV infec-
tion: male gender, young age, birth in the first half
of the RSV season, day-care attendance, crowding
in the home and siblings.32 In this study, we found
younger age and prematurity, congenital heart
disease and cerebral palsy were independent pre-
dictors of ICU care. We suggested that these find-
ings might be attributed not only to RSV infection,
but also to underlying diseases, for example the
impaired function of sputum clearance in patients
with cerebral palsy might result in respiratory fail-
ure and the subsequent need for ICU care. Also,
Chan et al assessed the effect of having a combi-
nation of risk factors on disease course, and re-
ported that children under 24 months of age with
both a history of prematurity and failure to thrive
were more likely to develop respiratory failure.33
However, we demonstrated that a great proportion
of our children had no underlying diseases pre-
disposing to admission to the ICU and endotra-
cheal tube intubation. This finding was consistent
with data published by other groups.10,34
RSV infection occurs mainly during fall and
winter in temperate countries,14 and during the
hot months and the rainy season in tropical cli-
mates.11,35 A biennial pattern with peaks in spring
and fall occurs in northern Taiwan20,36 but without
significant seasonality in southern Taiwan.18
Monthly intramuscular injection of palivizumab
in winter is currently recommended to high-risk
children as a prophylaxis for reducing the incidence
of hospitalization due to RSV infection.16,30,37
We found a biennial pattern with peaks in spring
and fall of RSV associated hospitalizations in this
study, which was also seen in the premature and
in patients with congenital heart diseases. Cost
effectiveness of RSV prophylaxis tended to be
more favorable in specific populations, including
premature infants born before 32 weeks gesta-
tional age, and infants or children aged < 2 years
with chronic lung disease or congenital heart dis-
ease.38 In our study, we found prematurity and
congenital heart diseases are the independent risk
factors of severe RSV infection and these patients
might be the candidates for the palivizumab pro-
phylaxis. However, the cost effectiveness of RSV
prophylaxis in Taiwan might need further study
as the biennial pattern the “RSV season” makes
the timing of prophylaxis different from other
countries.
One major limitation of this investigation is
that this retrospective study focused mainly on re-
ported data, and the true cases of RSV infections
might be underestimated. To our knowledge, RSV
infection is detected by using the rapid antigen
test or conventional virus cultures; however, these
detection methods are not available in all hospitals
in Taiwan. Besides, not all of the hospitalizations
caused by RSV infections were well examined and
coded as RSV infections, because the results may
have been pending before discharge, or due to
indiscretion. Most probably, these patients might
be tested for the possibility of RSV infection only
when they had severe symptoms and treatment in
medical centers. We need prospective surveillance
to monitor the epidemiology of RSV infections in
the community; collaboration of local clinics, re-
gional hospitals, and medical centers will provide
more details of RSV infections in Taiwan.
In summary, RSV infection is an important
health issue in children that occurs biennially in
Taiwan, with peaks in spring and fall. Patients with
underlying diseases needed longer hospital stay,
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ICU stay and incurred higher medical costs. We
found younger age, prematurity, congenital heart
disease and cerebral palsy were independent pre-
dictors of ICU care in Taiwanese children below
the age of 5 years. Public health goals could be ad-
vocated to reduce and prevent RSV disease burden
from children with underlying diseases and risks.
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